Patricia Deverka
Publications and Insights
- Publication: Novel devices: optimising drug delivery in multiple myeloma
- Publication: A global landscape analysis of access to tumour-agnostic therapies
- Publication: Achieving Accelerated Patient Access to Cancer Care in Europe
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Insight: How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
- Insight: Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
- Publication: An Analysis of NICE’s Optimised Decisions from 2015 to 2024
- Publication: Analysing Global Immunisation Expenditure
- Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
- Insight: Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
- Publication: A Spotlight on Haemophilia Therapies
- Publication: The Cost of Drug Shortages
- Insight: Drug shortages are on the rise – but what is their impact?
- Publication: Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
- Publication: How Have HTA Agencies Evolved Their Methods Over Time?
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Publication: The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Insight: Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
- Publication: Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
- Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
- Bulletin: Advancing HTA through collaboration
- Insight: Around The World in HTAs: Italy – What’s Next?
- Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
- Insight: Combination Therapies: A Step Forward to the Value Attribution Problem
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- Insight: New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
- Publication: When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
- Insight: Would Waiving COVID-19 Vaccines Patents Save Lives?
- Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
- Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
- Publication: Realising the Broader Value of Vaccines in the UK
- Publication: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
- Publication: A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
- Publication: International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
- Publication: Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
- Publication: Unrelieved Pain in Palliative Care in England
- Publication: The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
- Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
- Publication: The Future of Global Health Procurement: Issues around Pricing Transparency
- Publication: Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
- Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
- Publication: Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Establishing a Reasonable Price for an Orphan Drug
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Publication: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
- Publication: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
- Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
- Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
- Publication: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
- Publication: Policy Options for Formulary Development in Middle-income Countries
- Publication: Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
- Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
- Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
- Publication: Improving Efficiency and Resource Allocation in Future Cancer Care
- Publication: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
- Publication: International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
- Publication: Obstructive Sleep Apnoea: Health Economics Report
- Publication: Exploring the Interdependencies of Research Funders in the UK
- Publication: The Trajectory of Dementia in the UK – Making a Difference
- Publication: The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
- Publication: Projecting Expenditure on Medicines in the NHS: Second Edition
- Publication: The Influence of Cost-effectiveness and Other Factors on NICE Decisions
- Publication: Exploring the link between health and wealth in decision making
- Publication: Multi-Criteria Decision Analysis to Value Orphan Medicines
- Publication: Projecting Expenditure on Medicines in the NHS
- Publication: International Comparisons of Medicines Prices: 2011 Indices
- Publication: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
- Publication: Time Trends in NICE HTA Decisions
- Publication: Health and the Use of Medicines in Primary Care in Wales
- Publication: Exploring the Interdependency between Public and Charitable Medical Research
- Publication: Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
- Publication: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
- Publication: Shedding the Pounds: Obesity Management, NICE Guidance and Bariatric Surgery in England
- Publication: Using QALYs in Cancer: Review of the Methodological Limitations
- Publication: Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
- Publication: Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
- Publication: European Medicines Pricing and Reimbursement: Now and the Future
- Publication: Estimating Pharmaceutical Companies’ Value to the Nation: Case Study of the British Pharma Group